AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01916681
Drug: Misoprostol Alone
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol will be used alone to induce the patient
Trial: NCT00911612
Drug: Colesevelam
RxNorm normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days
Trial: NCT00163761
Drug: gemcitabine, vinorelbine, ifosfamide, filgastrim
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT00163761
Drug: gemcitabine, vinorelbine, filgastrim
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT03072589
Drug: Regadenoson infusion
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose escalation of Regadenoson when given as an infusion
Trial: NCT03973411
Drug: Prophylactic ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pacients will receibe prophylactic ondansetron plus standard spinal anesthesia
Trial: NCT04299893
Drug: Ozone
RxNorm normalized name: OZONE
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
Trial: NCT04299893
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
Trial: NCT01637454
Drug: Noradrenaline
RxNorm normalized name: Noradrenaline
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
Trial: NCT01637454
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour
Trial: NCT02254967
Drug: Fidaxomicin
RxNorm normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablets administered in an extended pulsed regimen
Trial: NCT02254967
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT01053663
Drug: Tamiflu
RxNorm normalized name: Tamiflu
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 doses over 5 or 6 days of which the first 5 or 6 doses must be intravenous, up to 5 days (10 doses) of additional intravenously or oral treatment if virus shedding continues at day 6
Trial: NCT00708214
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole at standard dosage
Trial: NCT03524235
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-Transplantation Bendamustine
Trial: NCT03524235
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-Transplantation Fludarabine
Trial: NCT03524235
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pre-Transplantation Rituximab (Rituximab for lymphoma diagnosis only)
Trial: NCT00555464
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine (0.05 mg/kg/dose) will be administered into a vein (PICC line) every week for 12 weeks. If assigned to receive Vincristine, a PICC line will be placed by a doctor who is a specialist in this procedure, an interventional radiologist. This will require sedation and when possible, will be coordinated with sedation for the MRI.
Trial: NCT00555464
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone given at 3 mg/kg/day by mouth for 12 week
Trial: NCT01073904
Drug: Levonorgestrel Emergency Pill (BAY86-5028)
RxNorm normalized name: levonorgestrel Pill
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of 1.5 mg coated tablet
Trial: NCT02579564
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02579564
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02579564
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02579564
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02579564
Drug: Endostar
RxNorm normalized name: Endostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02579564
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04069325
Drug: febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tablets, 40 mg once daily (QD), oral, 12 weeks
Trial: NCT01250873
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: po administration
Trial: NCT04594369
Drug: Brensocatib 10 mg
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT04594369
Drug: Brensocatib 25 mg
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT01214083
Drug: High-dose naltrexone (150 mg) alone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be evaluated weekly for 12 weeks.
Trial: NCT01214083
Drug: Low-dose naltrexone (50 mg) alone
RxNorm normalized name: ethinyl estradiol
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be evaluated weekly for 12 weeks.
Trial: NCT03181802
Drug: Botox
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: single injection of 200 International Unit of BoNT-A in 10 bilateral paravertebral intramuscular points for treating chronic LBP
Trial: NCT03406819
Drug: Nitroprusside Sodium
RxNorm normalized name: nitroprusside sodium
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracoronary infusion 50\~100μg each time (repeated)
Trial: NCT03406819
Drug: Tirofiban Hydrochloride
RxNorm normalized name: Tirofiban Hydrochloride
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion 10μg/kg for single time
Trial: NCT00169000
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 over one hour on day 8 of each cycle
Trial: NCT02880280
Drug: Human Menopausal Gonadotropin
RxNorm normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
Trial: NCT02662725
Drug: IPILIMUMAB
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04123925
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Locally advanced colon cancer must be documented at screening (within 21 days prior to initiation of study treatment) and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan Postoperatively, standard adjuvant chemotherapy will be administered in pathological III-stage and at investigator discretion in pathological II-stage at high risk
Trial: NCT03705195
Drug: Gliclazide
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose liquid gliclazide will be used with the second matched clamp (OGTT/IGII) in visits 4 \& 5.
Trial: NCT01903421
Drug: Spinal anesthesia group: bupivacaine 10-15mg
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00498979
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: recombinant interferon alfa-2b
Trial: NCT00498979
Drug: sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium stibogluconate
Trial: NCT00498979
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dacarbazine
Trial: NCT00498979
Drug: vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vinblastine
Trial: NCT04186013
Drug: Atezolizumab Injection [Tecentriq]
RxNorm normalized name: atezolizumab Injection [Tecentriq]
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous infusion of 1.200 mg of Atezolizumab administered intravenously every 3 weeks for a total of 6 doses
Trial: NCT02880280
Drug: Human Chorionic Gonadotropin
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
Trial: NCT02865499
Drug: acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acarbose treatment with meals
Trial: NCT02792192
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered as per the schedule specified in respective arm.
Trial: NCT03004625
Drug: daclatasvir
RxNorm normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: to evaluate the treatment efficacy and safety of the drug in HCV patients
Trial: NCT03004625
Drug: asunaprevir
RxNorm normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: to evaluate the treatment efficacy and safety of the drug in HCV patients
Trial: NCT03004625
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: to evaluate the treatment efficacy and safety of the drug in HCV patients
Trial: NCT02887248
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction: 125 mg/m² by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles to be given with Gemcitabine.~Maintenance: single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment.
Trial: NCT02887248
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction: 1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles.
Trial: NCT02949843
Drug: Targeted Molecular Therapy
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive drug targeting secondary mutation
Trial: NCT02524743
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated lidocaine (20 mg and 40 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
Trial: NCT00056654
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg Intramuscular injection 6 month depot formulation
Trial: NCT02934932
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
Trial: NCT00000492
Drug: propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01307800
Drug: LY2140023
RxNorm normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00065936
Drug: Naltrexone hydrochloride
RxNorm normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00421018
Drug: Single corticosteroid inhalers and Singulair
RxNorm normalized name: abiraterone and corticosteroids
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment steps according to preset algorithm
Trial: NCT00237224
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00299897
Drug: SP01A
RxNorm normalized name: Sulfapyridine
DrugBank: Sulfapyridine (DB00891)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00650325
Drug: Sertraline Hydrochloride Tablets 100 mg
RxNorm normalized name: sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fasting
Trial: NCT02993926
Drug: Enantone
RxNorm normalized name: Prasterone enantate
DrugBank: Prasterone enantate (DB16625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enantone suspension for injection
Trial: NCT02993926
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A non-Enantone GnRH agonist
Trial: NCT01148160
Drug: voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous, oral administration
Trial: NCT01981941
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01303406
Drug: Idebenone
RxNorm normalized name: Idebenone
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: All PROTI patients randomised to idebenone treatment will receive high dose idebenone. This is defined according to body weight. In patients weighing 45 kg or less, it is 1350 mg/day (3 x 150 mg tablets three times per day with meals). In patients weighing more than 45 kg, it is 2250 mg/day (5 x 150 mg tablets three times per day with meals).
Trial: NCT00356356
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept 50 mg/wk administered as 2-25 mg SQ injections at separate injection sites
Trial: NCT03014297
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: everolimus
Trial: NCT03014297
Drug: fosbretabulin
RxNorm normalized name: Fosbretabulin
DrugBank: Fosbretabulin (DB12577)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosbretabulin
Trial: NCT03437044
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
Trial: NCT03437044
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
Trial: NCT01599806
Drug: Ceftazidime - Avibactam ( CAZ-AVI)
RxNorm normalized name: avibactam / ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
Trial: NCT01599806
Drug: Doripenem
RxNorm normalized name: Doripenem
DrugBank: Doripenem (DB06211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
Trial: NCT01599806
Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Trial: NCT01599806
Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Trial: NCT02201667
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180-mg loading dose followed by 90mg twice daily for 30 days
Trial: NCT02201667
Drug: clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300-mg loading dose followed by 75mg once daily for 30 days.
Trial: NCT02201667
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg loading dose aspirin and followed by 100mg once daily
Trial: NCT03612947
Drug: Bupivacaine only
RxNorm normalized name: Bupivacaine only product
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
Trial: NCT04675697
Drug: Platinum-etoposide+Anlotinib
RxNorm normalized name: platinum
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Platinum-etoposide regiment consisted of etoposide 100mg/m2, d1\~3 of 21-day cycle, with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5\~6, Q3W). Anlotinib treated of 12mg Qd from day 1 to 14 of a 21-day cycle. Eligible patients received anlotinib plus platinum-etoposide for 4\~6 cycles, and followed by maintenance therapy with Anlotinib. The efficacy was evaluated every 6 weeks (2 cycles) through treatment.
Trial: NCT02189304
Drug: PT010
RxNorm normalized name: Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
Trial: NCT02189304
Drug: PT009
RxNorm normalized name: Budesonide/Formoterol Fumarate Dihydrate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PT009 administered as 2 inhalations
Trial: NCT02351739
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02351739
Drug: ACP-196 in combination with pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00432211
Drug: Avotermin
RxNorm normalized name: avotermin
DrugBank: Avotermin (DB11955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.~Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration.